Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)
Taiwan · Delayed Price · Currency is TWD 7.20
-0.05 (-0.69%)
Sep 15, 2026, 1:20 PM CST
TPEX:4186 Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 823 | 1,004 | 1,418 | 1,485 | 1,593 | 1,674 | |
Market Cap Growth | -36.31% | -29.21% | -4.54% | -6.78% | -4.84% | -26.63% |
Enterprise Value | 959 | 1,145 | 1,566 | 1,648 | 1,716 | 1,780 |
Last Close Price | 9.14 | 11.15 | 15.75 | 16.50 | 17.70 | 18.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 52.70 | 35.78 | 61.97 | - | 502.52 | - |
PS Ratio | 2.36 | 2.75 | 4.00 | 4.70 | 5.01 | 6.88 |
PB Ratio | 3.06 | 3.52 | 5.53 | 6.35 | 6.51 | 6.93 |
P/TBV Ratio | 3.07 | 3.52 | 5.53 | 6.35 | 6.61 | 7.24 |
P/FCF Ratio | 41.09 | 50.76 | 324.59 | 2226.39 | - | - |
P/OCF Ratio | 15.08 | 18.89 | 170.23 | 117.78 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.75 | 3.14 | 4.42 | 5.22 | 5.39 | 7.31 |
EV/EBITDA Ratio | 20.76 | 22.15 | 26.14 | 66.04 | 55.41 | - |
EV/EBIT Ratio | 35.82 | 30.63 | 34.92 | 386.01 | 225.46 | - |
EV/FCF Ratio | 47.89 | 57.91 | 358.55 | 2470.58 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.10 | 0.93 | 0.90 | 1.31 | 1.14 | 1.03 |
Debt / EBITDA Ratio | 6.37 | 4.63 | 3.51 | 10.18 | 7.81 | - |
Debt / FCF Ratio | 14.70 | 13.36 | 52.59 | 460.63 | - | - |
Net Debt / Equity Ratio | 0.51 | 0.43 | 0.48 | 0.54 | 0.50 | 0.37 |
Net Debt / EBITDA Ratio | 3.33 | 2.39 | 2.06 | 5.01 | 3.91 | -1.15 |
Net Debt / FCF Ratio | 6.81 | 6.24 | 28.24 | 187.56 | -4.35 | -1.41 |
Asset Turnover | 0.48 | 0.51 | 0.50 | 0.43 | 0.45 | 0.32 |
Inventory Turnover | 6.27 | 6.29 | 5.53 | 5.27 | 5.29 | 4.83 |
Quick Ratio | 0.88 | 0.88 | 0.85 | 0.74 | 0.91 | 0.93 |
Current Ratio | 0.98 | 0.98 | 0.96 | 0.82 | 1.07 | 1.09 |
Return on Equity (ROE) | 6.05% | 10.36% | 9.33% | -4.46% | 1.30% | -39.48% |
Return on Assets (ROA) | 2.32% | 3.28% | 3.93% | 0.37% | 0.67% | -8.36% |
Return on Invested Capital (ROIC) | 6.61% | 9.49% | 12.14% | 1.18% | 1.88% | -28.58% |
Return on Capital Employed (ROCE) | 5.70% | 7.90% | 10.20% | 1.00% | 1.60% | -21.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.92% | 2.79% | 1.61% | -0.72% | 0.20% | -7.08% |
FCF Yield | 2.43% | 1.97% | 0.31% | 0.04% | -1.75% | -3.78% |
Buyback Yield / Dilution | - | - | - | - | - | -11.05% |